BioCryst Pharmaceuticals Inc (BCRX)
7.62
+0.04
(+0.53%)
USD |
NASDAQ |
Sep 27, 16:00
7.62
0.00 (0.00%)
After-Hours: 20:00
BioCryst Pharmaceuticals Accounts Receivable (Quarterly): 68.76M for June 30, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 68.76M |
March 31, 2024 | 60.59M |
December 31, 2023 | 56.95M |
September 30, 2023 | 53.65M |
June 30, 2023 | 57.67M |
March 31, 2023 | 48.64M |
December 31, 2022 | 50.60M |
September 30, 2022 | 42.61M |
June 30, 2022 | 41.49M |
March 31, 2022 | 36.42M |
December 31, 2021 | 29.41M |
September 30, 2021 | 26.21M |
June 30, 2021 | 27.62M |
March 31, 2021 | 18.39M |
December 31, 2020 | 8.646M |
September 30, 2020 | 5.422M |
June 30, 2020 | 3.997M |
March 31, 2020 | 5.642M |
December 31, 2019 | 22.15M |
September 30, 2019 | 3.598M |
June 30, 2019 | 3.602M |
March 31, 2019 | 5.002M |
December 31, 2018 | 4.293M |
September 30, 2018 | 3.394M |
June 30, 2018 | 2.342M |
Date | Value |
---|---|
March 31, 2018 | 5.694M |
December 31, 2017 | 6.117M |
September 30, 2017 | 8.985M |
June 30, 2017 | 3.325M |
March 31, 2017 | 9.564M |
December 31, 2016 | 8.768M |
September 30, 2016 | 5.968M |
June 30, 2016 | 2.234M |
March 31, 2016 | 7.384M |
December 31, 2015 | 6.243M |
September 30, 2015 | 7.495M |
June 30, 2015 | 4.296M |
March 31, 2015 | 5.594M |
December 31, 2014 | 9.49M |
September 30, 2014 | 3.238M |
June 30, 2014 | 0.897M |
March 31, 2014 | 3.28M |
December 31, 2013 | 2.115M |
September 30, 2013 | 2.369M |
June 30, 2013 | 1.024M |
March 31, 2013 | 4.325M |
December 31, 2012 | 4.562M |
September 30, 2012 | |
June 30, 2012 | |
March 31, 2012 |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
3.598M
Minimum
Sep 2019
68.76M
Maximum
Jun 2024
33.42M
Average
32.91M
Median
Accounts Receivable (Quarterly) Benchmarks
Novavax Inc | 32.10M |
AIM ImmunoTech Inc | 0.00 |
Perspective Therapeutics Inc | 0.142M |
Protalix BioTherapeutics Inc | 10.13M |
Armata Pharmaceuticals Inc | -- |